Preparation and Evaluation of Gemifloxacin Mesylate Floating Matrix Tablets in Healthy Human Volunteers
DOI:
https://doi.org/10.37285/ijpsn.2017.10.1.8Abstract
The purpose of present investigation was to develop floating matrix tablets of gemifloxacin mesylate, which after oral administration could prolong the gastric residence time, increase the drug bioavailability and diminish the side effects of irritating drugs. Tablets containing drug, various viscosity grades of hydroxypropyl methylcellulose such as HPMC K4M and HPMC K15M as matrix forming agent, Sodium bicarbonate as gas-forming agent and different additives were tested for their usefulness in formulating gastric floating tablets by direct compression method. The physical parameters, in vitro buoyancy, release characteristics and in vivo radiographic study were investigated in this study. The gemifloxacin mesylate floating tablets were prepared using HPMC K4M polymer giving more sustained drug release than the tablet containing HPMC K15M. All these formulations showed floating lag time of 30 to 47 sec and total floating time more than 12 h. The drug release was decreased when polymer concentration increases and gas generating agent decreases. Formulation that contains maximum concen-tration of both HPMC K15M and sodium bicarbonate (F9) showing sufficiently sustained with 99.2% of drug release at 12 h. The drug release from optimized formulation follows Higuchi model that indicates the diffusion controlled release. The best formulation (F9) was selected based on in vitro characteristics and used in vivo radiographic studies by incorporating barium sulphate as a radio-opaque agent and the tablet remained in the stomach for about 6 h.
Downloads
Metrics
Keywords:
Gemifloxacin, HPMC, Higuchi model, Radiographic study,, Buoyancy, floating drug delivery.
Downloads
Published
How to Cite
Issue
Section
References
Banker G. S, Anderson N. R (2008). Tablets in Lachman, L. Lieberman. The theory and practice of industrial pharmacy. 3rd editionLea & Febige, 293-342.
Baumgartner S, Kristl J, Vrecer F, Vodopivec P, Zorko B (2000). Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int J Pharm 195: 125-135.
Brahma N.S and Kwon H.K (2000). Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. Control. Release 63: 235-259.
Cedillo-Ramírez E, Villafuerte-Robles L, Hernández-León A. (2006). Effect of added Pharmatose DCL11 on the sustained release of metronidazole from Methocel K4M and Carbopol 971P NF -floating matrices. Drug Dev Ind Pharm 32: 955-965.
Cooper J, Gunn C (1986). ‘Powder flow and compaction’, in Carter, S.J. (ed.) Tutorial pharmacy, New Delhi: CBS Publishers and Distributors, 211-233.
Dave B.S, Amin A.F, Patel M.M (2005). Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. AAPS. Pharm. Sci. Technol 5: 77-82.
Desai S, Bolton S (1993). A floating controlled-release drug delivery system: In vitro-in vivo evaluation. Pharm Res 10: 1321-1325.
Gergogiannis YS, Rekkas DM, Dallos PP, Chailis NH (1993). Floating and swelling characteristics of various excipients used in controlled release technology. Drug Dev Ind Pharm 19: 1061-81.
Hilton AK and Deasy PB (1992). In vitro and in vivo evaluation of an oral sustained release floating dosage form of amoxicillin trihydrate. Int J Pharm 86: 79-88.
Koteshwar Rao G, Praveen Kumar M, Rajendraprasad M and Prabhakar Reddy V (2013). Development and in vivo evaluation of gastroretentive delivery systems for cefuroxime axetil. Saudi Pharm J 21(1): 53-59.
Kumar RAA, Rao CSG and Reddy PV (2009). Formulation and evaluation of swellable and floating gastroretentive ciprofloxacin hydrochloride Tablets. AAPS Pharm Sci Tech. 10: 220-226.
Li S, Lin S, Daggy BP, Mirchandani HL and Chien YW (2003). Effect of HPMC and Carbopol on the release and floating properties of Gastric Floating Drug Delivery System using factorial design. Int J Pharm 253:13-22.
Liandong Hu, Li Li, Xun Yang, Wei Liu, Jianxue Yang, Yanhong Jia, Chuang Shang and Hongxin Xu (2011). Floating matrix dosage form for dextromethorphan hydrobromide based on gas forming technique: In vitro and in vivo evaluation in healthy volunteers. Eur J Pharm Sci 42: 99-105.
Mahesh C, Paras J, Sachin C, Rajesh S, and Pradeep V (2005). Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation. Int J Pharm 304: 178-184.
Menon A, Ritschel WA and Sakr A (1994). Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci 83: 239-245.
Moes AJ (1993). Gastroretentive dosage forms. Crit. Rev. Ther. Drug Carrier Syst 10: 143-195.
Mutalik S, Reddy KR and Reddy S (2003). Once daily sustained release matrix tablets of nicorandil: Formulation and in vitro evaluation, AAPS PharmSciTech. 4: 1-9
Narendra C, Srinath MS and Babu G (2006). Optimization of bilayer floating tablet containing metoprolol tartrate as a model drug for gastric retention. AAPS Pharm SciTech 7: E34.
Sheth PR and Tossounian J (1984). Hydro dynamically balanced system (HBSTM): A novel drug delivery system for oral use. Drug Dev Ind Pharm 10: 313-339.
Singh BN and Kim KH (2000). Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J Control Release 63: 235-259.
Srivastava AK, Wadhwa S, Ridhurkar D, and Misha B. (2005). Oral sustained delivery of atenolol from floating matrix tablets-formulation and in vitro evaluation. Drug Dev Ind Pharm 31: 367-374.
Timmermans J and Moes AJ (1994). Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: New data for reconsidering the controversy. J Pharm Sci 83: 18-24.
Xiaoqiang X, Minjie S, Feng Z and Yiqiao H (2006). Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: In vitro and in vivo evaluation in healthy volunteers. Int J Pharm 310: 139-145.
